#USA #Fremont #Alamar Biosciences #NULISAqpcr #Biomarker Assay

Alamar Biosciences Unveils NULISAqpcr™ Custom Assay Development Kit

In a significant advancement for clinical research, Alamar Biosciences has introduced the NULISAqpcr™ Custom Assay Development Kit, designed to accelerate the development of new biomarker assays. This innovative kit allows researchers to create highly sensitive and precise assays tailored to their specific research needs, utilizing the company’s cutting-edge NULISA™ technology.

A New Standard in Proteomics

Alamar Biosciences, headquartered in Fremont, California, is known for its work in precision proteomics aimed at the early detection of diseases. The NULISAqpcr™ platform sets a new standard in biomarker detection, achieving attomolar sensitivity that enables unprecedented accuracy and quantitation in assays. By utilizing this platform, researchers can leverage advanced proteomic analysis techniques to push the boundaries of current biomarker research.

With this Custom Assay Development Kit, scientists are given unmatched flexibility, as they can incorporate their own antibodies to develop targeted assays that exhibit exceptional sensitivity and reproducibility. This feature is particularly appealing to fields requiring high sensitivity and extensive dynamic ranges, such as immunology and neurology.

Streamlined Workflow from Antibody Conjugation to Automated Analysis

The NULISAqpcr™ Custom Assay Development Kit is designed to streamline the workflow from antibody conjugation through to automated NULISAqpcr. Utilizing the ARGO™ HT device, researchers can execute a seamless protocol that simplifies the process of developing custom single-plex assays. This not only enhances productivity but also contributes to consistency in experimental results across different research environments.

Dr. Yuling Luo, Founder, Chairman, and CEO of Alamar Biosciences, highlighted the importance of this product launch. “The Custom Assay Development Kit is a direct response to the growing demand from researchers seeking to harness our state-of-the-art NULISA technology for developing powerful biomarker assays aimed at translational and clinical research,” he remarked. This development marks a significant milestone in Alamar’s mission to build a transformative ecosystem for precision proteomics.

Commitment to Innovation and Scientific Community Support

The introduction of the NULISAqpcr Custom Assay Development Kit underscores Alamar’s commitment to driving innovation within the scientific community. By providing researchers with tools that facilitate the development of powerful, tailored assays, Alamar aims to support advancements in clinical research and diagnostics.

The NULISAqpcr Custom Assay Development Kit is now available for order and is set to ship in the second quarter of this year. As a private biosciences company, Alamar Biosciences aims to advance precision proteomics, ensuring tools are aligned with the latest breakthroughs in genomics to achieve detection sensitivities surpassing existing protein detection technologies on the market.

For more details, visit their official website or watch the introductory video showcasing the capabilities of the NULISAqpcr technology: Watch Video.

In conclusion, the launch of the NULISAqpcr™ Custom Assay Development Kit represents a crucial development not only for Alamar Biosciences but also for the broader clinical research landscape, paving the way for enhanced biomarker discovery and validation, and ultimately leading to better patient outcomes.